This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Biotech is roughly tied for second place with consumer health, dropping also by 7 points. There’s another piece of math worth doing here: a chasm between biotech and pharma of 17 percentage points worth of trust — that is the difference between the 55% of American trusting biotech versus 38% trusting pharma.
One of the biggest gambles in biotech history is about to be tested on Wall Street. In its prospectus, Moderna set an initial target of $500 million for the offering, which would make it the largest biotech IPO in history. Unlike a typical biotech going public, Moderna has a pipeline of 21 programs, 10 of which are in human testing.
in 2010 to 11.4% The company will supply solutions to AstraZeneca while extending services to pharma, biotech companies, and clinical research organizations. In a recent review paper appeared on Nature , Mittermaier et al. reported a substantial increase in the use of DHTs, from 0.7%
In October 2010, the US Federal Communications Commission and the US Food and Drug Administration (FDA) partnered to encourage investment in wireless healthcare devices, and the European authorities have become increasingly willing to give such solutions the CE marking required on drug products to be sold in Europe.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content